Genmab (Otc) (GMAB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Genmab’s TIVDAK has received full FDA approval for treating patients with recurrent or metastatic cervical cancer after showing an overall survival benefit in a Phase 3 study. TIVDAK is the first antibody-drug conjugate for this patient group that has demonstrated positive survival data compared to chemotherapy. This approval marks a significant advancement for women with advanced cervical cancer, offering a new treatment option where limited options existed before.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
